江中藥業(600750.SH):簽署海斯製藥的股權重組協議
格隆匯9月21日丨江中藥業(600750.SH)公佈,公司第八屆董事會第十八次會議審議通過《關於以股權轉讓及增資方式收購海斯製藥51%股權的議案》,公司決定通過公開摘牌方式取得晉城海斯製藥有限公司(以下簡稱:"海斯製藥")36%股權;若摘牌成功,後續計劃通過增資方式將持有海斯製藥的股權比例由36%增加至51%。
2021年9月17日,《晉城海斯製藥有限公司36%股權交易》掛牌截止,僅有江中藥業一家意向受讓方報名,公司將按照11,902.3704萬元受讓價辦理產權過户手續,並在股權轉讓完成後進行增資。2021年9月18日,公司與晉能控股裝備製造集團有限公司、晉城王台科工貿有限公司、中國疾病預防控制中心傳染病預防控制所、海斯製藥簽署《關於海斯製藥之股權重組協議》。
根據協議,各方一致同意,甲方江中藥業先通過產權交易所公開掛牌方式受讓股權,具體如下:乙方晉能控股裝備製造集團將持有的目標公司晉城海斯製藥25.7102%股權,丙方晉城王台科工貿將持有的目標公司10.2898%股權,兩方合計36%股權,以股權評估價值33,062.14萬元為基礎,確定股權轉讓價格,通過產權交易所公開掛牌方式對外聯合轉讓;甲方擬受讓上述目標公司36%股權。(2021年9月17日,《晉城海斯製藥有限公司36%股權交易》掛牌截止,僅有江中藥業一家意向受讓方報名,公司將按照11,902.3704萬元受讓價辦理產權過户手續)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.